Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules

Launched by CHINESE PLA GENERAL HOSPITAL · Dec 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called ultrasound-guided thermal ablation for thyroid nodules that have been classified as Bethesda III or IV. These classifications indicate that the nodules may have some potential for cancer, but further testing is needed to determine their nature. The goal of the trial is to see how well this treatment works over the long term for patients who do not want or cannot have surgery.

To be eligible for this trial, participants must have a confirmed Bethesda III or IV diagnosis from a needle biopsy and must not show signs of spread or advanced disease in their thyroid or surrounding areas. They should also have refused surgery or be unable to undergo it for some reason. Participants will need to be followed for at least 12 months after the treatment to monitor the results. This trial is open to all adults aged 65 to 74, and it aims to provide valuable information on the safety and effectiveness of this treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. confirmation of Bethesda III or IV on fine- needle aspiration and negative on Braf V600E test
• • 2. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT
• • 3. refusal or ineligibility for surgery
• • 4. follow-up time ≥12 months
• Exclusion Criteria:
• • 1. follicular neoplasm or malignancy findings on biopsy
• • 2. no suspicious of malignancy in US
• • 3. patients with contra-lateral vocal cord paralysis
• • 4. follow- up time less than 12 months